Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
Ponnusamy S, He Y, Hwang DJ, Thiyagarajan T, Houtman R, Bocharova V, Sumpter BG, Fernandez E, Johnson D, Du Z, Pfeffer LM, Getzenberg RH, McEwan IJ, Miller DD, Narayanan R.
Ponnusamy S, et al. Among authors: pfeffer lm.
Clin Cancer Res. 2019 Nov 15;25(22):6764-6780. doi: 10.1158/1078-0432.CCR-19-1458. Epub 2019 Sep 3.
Clin Cancer Res. 2019.
PMID: 31481513